{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:26:47Z","timestamp":1781018807982,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"DOI":"10.7759\/cureus.70631","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T15:28:26Z","timestamp":1727796506000},"source":"Crossref","is-referenced-by-count":4,"title":["Harnessing Epigenetic Mechanisms to Overcome Immune Evasion in Cancer: The Current Strategies and Future Directions"],"prefix":"10.7759","author":[{"given":"Rajabikramaditya","family":"Panda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Vellapandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S272031","article-title":"Epigenome-driven strategies for personalized cancer immunotherapy","volume":"15","author":"Rocha GI","year":"2023","unstructured":"Rocha GI, Gomes JE, Leite ML, da Cunha NB, Costa FF. Epigenome-driven strategies for personalized cancer immunotherapy. Cancer Manag Res. 2023, 15:1351-67. 10.2147\/CMAR.S272031","journal-title":"Cancer Manag Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner RC","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021, 11:69. 10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin MJ","year":"2022","unstructured":"Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022, 3:911-26. 10.1038\/s43018-022-00418-6","journal-title":"Nat Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01480-x","article-title":"Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets","volume":"8","author":"Yang J","year":"2023","unstructured":"Yang J, Xu J, Wang W, Zhang B, Yu X, Shi S. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023, 8:210. 10.1038\/s41392-023-01480-x","journal-title":"Signal Transduct Target Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01154-x","article-title":"DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application","volume":"13","author":"Hu C","year":"2021","unstructured":"Hu C, Liu X, Zeng Y, Liu J, Wu F. DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application. Clin Epigenetics. 2021, 13:166. 10.1186\/s13148-021-01154-x","journal-title":"Clin Epigenetics"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00945-8","article-title":"Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application","volume":"13","author":"Sun YM","year":"2020","unstructured":"Sun YM, Chen YQ. Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application. J Hematol Oncol. 2020, 13:109. 10.1186\/s13045-020-00945-8","journal-title":"J Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-023-10104-3","article-title":"Oncogenic signaling-mediated regulation of chromatin during tumorigenesis","volume":"42","author":"Alam J","year":"2023","unstructured":"Alam J, Huda MN, Tackett AJ, Miah S. Oncogenic signaling-mediated regulation of chromatin during tumorigenesis. Cancer Metastasis Rev. 2023, 42:409-25. 10.1007\/s10555-023-10104-3","journal-title":"Cancer Metastasis Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-023-00598-6","article-title":"Interpreting non-coding disease-associated human variants using single-cell epigenomics","volume":"24","author":"Gaulton KJ","year":"2023","unstructured":"Gaulton KJ, Preissl S, Ren B. Interpreting non-coding disease-associated human variants using single-cell epigenomics. Nat Rev Genet. 2023, 24:516-34. 10.1038\/s41576-023-00598-6","journal-title":"Nat Rev Genet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02037-2","article-title":"Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes","volume":"40","author":"Malayil R","year":"2023","unstructured":"Malayil R, Chhichholiya Y, Vasudeva K, Singh HV, Singh T, Singh S, Munshi A. Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes. Med Oncol. 2023, 40:174. 10.1007\/s12032-023-02037-2","journal-title":"Med Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.04.004","article-title":"Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity","volume":"3","author":"Wainwright EN","year":"2017","unstructured":"Wainwright EN, Scaffidi P. Epigenetics and cancer stem cells: unleashing, hijacking, and restricting cellular plasticity. Trends Cancer. 2017, 3:372-86. 10.1016\/j.trecan.2017.04.004","journal-title":"Trends Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20210084","article-title":"The roles of epigenetics in cancer progression and metastasis","volume":"478","author":"Chen JF","year":"2021","unstructured":"Chen JF, Yan Q. The roles of epigenetics in cancer progression and metastasis. Biochem J. 2021, 478:3373-93. 10.1042\/BCJ20210084","journal-title":"Biochem J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11010169","article-title":"Targeting epigenetic mechanisms: a boon for cancer immunotherapy","volume":"11","author":"Parab A","year":"2023","unstructured":"Parab A, Kumar Bhatt L, Omri A. Targeting epigenetic mechanisms: a boon for cancer immunotherapy. Biomedicines. 2023, 11:10.3390\/biomedicines11010169","journal-title":"Biomedicines"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071061","article-title":"Epigenetic mechanisms of resistance to immune checkpoint inhibitors","volume":"10","author":"Perrier A","year":"2020","unstructured":"Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Epigenetic mechanisms of resistance to immune checkpoint inhibitors. Biomolecules. 2020, 10:10.3390\/biom10071061","journal-title":"Biomolecules"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00356-0","article-title":"New insights into epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities","volume":"11","author":"Dai M","year":"2022","unstructured":"Dai M, Liu M, Yang H, K\u00fc\u00e7\u00fck C, You H. New insights into epigenetic regulation of resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022, 11:101. 10.1186\/s40164-022-00356-0","journal-title":"Exp Hematol Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.12.019","article-title":"Combining epigenetic and immune therapy to overcome cancer resistance","volume":"65","author":"Gomez S","year":"2020","unstructured":"Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin Cancer Biol. 2020, 65:99-113. 10.1016\/j.semcancer.2019.12.019","journal-title":"Semin Cancer Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17689","article-title":"Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome","volume":"195","author":"Chien KS","year":"2021","unstructured":"Chien KS, Kim K, Nogueras-Gonzalez GM, et al.. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021, 195:378-87. 10.1111\/bjh.17689","journal-title":"Br J Haematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.121.000758","article-title":"5-Aza-4'-thio-2'-deoxycytidine, a new orally bioavailable nontoxic \"best-in-class\": DNA methyltransferase 1-depleting agent in clinical development","volume":"379","author":"Parker WB","year":"2021","unstructured":"Parker WB, Thottassery JV. 5-Aza-4'-thio-2'-deoxycytidine, a new orally bioavailable nontoxic \"best-in-class\": DNA methyltransferase 1-depleting agent in clinical development. J Pharmacol Exp Ther. 2021, 379:211-22. 10.1124\/jpet.121.000758","journal-title":"J Pharmacol Exp Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02025-6","article-title":"The roles of EZH2 in cancer and its inhibitors","volume":"40","author":"Liu Y","year":"2023","unstructured":"Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. Med Oncol. 2023, 40:167. 10.1007\/s12032-023-02025-6","journal-title":"Med Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28073043","article-title":"BET bromodomain inhibitors: novel design strategies and therapeutic applications","volume":"28","author":"To KK","year":"2023","unstructured":"To KK, Xing E, Larue RC, Li PK. BET bromodomain inhibitors: novel design strategies and therapeutic applications. Molecules. 2023, 28:10.3390\/molecules28073043","journal-title":"Molecules"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ht9010006","article-title":"Factors influencing epigenetic mechanisms: is there a role for bariatric surgery?","volume":"9","author":"Metere A","year":"2020","unstructured":"Metere A, Graves CE. Factors influencing epigenetic mechanisms: is there a role for bariatric surgery?. High Throughput. 2020, 9:10.3390\/ht9010006","journal-title":"High Throughput"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman AD","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020, 20:651-68. 10.1038\/s41577-020-0306-5","journal-title":"Nat Rev Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al..  Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51662","article-title":"Epigenetic alterations that are the backbone of immune evasion in T-cell malignancies","volume":"16","author":"Andreescu M","year":"2024","unstructured":"Andreescu M. Epigenetic alterations that are the backbone of immune evasion in T-cell malignancies. Cureus. 2024, 16:e51662. 10.7759\/cureus.51662","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01020-1","article-title":"Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential","volume":"55","author":"Xu X","year":"2023","unstructured":"Xu X, Peng Q, Jiang X, et al.. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp Mol Med. 2023, 55:1357-70. 10.1038\/s12276-023-01020-1","journal-title":"Exp Mol Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13548","article-title":"DNA methyltransferase inhibitor exposure-response: challenges and opportunities","volume":"16","author":"Kagan AB","year":"2023","unstructured":"Kagan AB, Garrison DA, Anders NM, Webster JA, Baker SD, Yegnasubramanian S, Rudek MA. DNA methyltransferase inhibitor exposure-response: challenges and opportunities. Clin Transl Sci. 2023, 16:1309-22. 10.1111\/cts.13548","journal-title":"Clin Transl Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor BC","year":"2022","unstructured":"Taylor BC, Balko JM. Mechanisms of MHC-I downregulation and role in immunotherapy response. Front Immunol. 2022, 13:844866. 10.3389\/fimmu.2022.844866","journal-title":"Front Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/298116-harnessing-epigenetic-mechanisms-to-overcome-immune-evasion-in-cancer-the-current-strategies-and-future-directions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T15:28:28Z","timestamp":1727796508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/298116-harnessing-epigenetic-mechanisms-to-overcome-immune-evasion-in-cancer-the-current-strategies-and-future-directions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.70631","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}